{Reference Type}: Journal Article
{Title}: Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes.
{Author}: Muto Y;Kambayashi Y;Kato H;Mizuhashi S;Ito T;Maekawa T;Ishizuki S;Uchi H;Matsushita S;Yamamoto Y;Yoshino K;Fujisawa Y;Amagai R;Ohuchi K;Hashimoto A;Fukushima S;Asano Y;Fujimura T;
{Journal}: Cancers (Basel)
{Volume}: 16
{Issue}: 15
{Year}: 2024 Aug 2
{Factor}: 6.575
{DOI}: 10.3390/cancers16152755
{Abstract}: <B>BACKGROUND: </B>Adjuvant therapy has improved the clinical prognosis for postoperative melanoma patients. However, the long-term efficacy of this therapy on the melanoma acral and mucosal subtypes has not been fully evaluated in previous trials. This study assessed the 3-year recurrence-free survival and overall survival of patients with melanoma, including the acral and mucosal subtypes, treated with anti-PD-1 antibody (Ab) or with the combination of the BRAF and MEK inhibitors dabrafenib and trametinib.<BR><B>METHODS: </B>We retrospectively analyzed both the 3-year time to relapse (TTR) and overall survival (OS) of 120 patients treated with anti-PD-1 antibody (Ab), or with the combination of dabrafenib and trametinib.<BR><B>RESULTS: </B>The overall median TTR was 18.4 months, with a range of 0.69 to 36 months. The 3-year TTR of the acral and mucosal types was 28.1% and 38.5%, respectively. Baseline tumor thickness (TT) and acral type were associated with the TTR in subgroup analysis. Moreover, we classified 104 acral and non-acral cutaneous patients into the anti-PD-1 Abs or dabrafenib plus trametinib combined therapies cohort in multiple analyses. The acral subtype and TT were detected as important prognostic factors. In the 3-year OS, only tumor ulceration was associated with the OS in both univariate and multiple analyses. There was no significant difference in baseline or treatment-related factors of the mucosal type (p > 0.05).<BR><B>CONCLUSIONS: </B>This study suggests that adjuvant therapy is more effective with non-acral cutaneous melanoma than either the acral or mucosal types at the 3-year TTR endpoint.